Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982993 · ClinicalTrials.gov registry record
Hepatitis C Infection in World Trade Center Responders
A clinical trial of Hepatitis C Infection, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 3,906
- Enrollment target
- 1
- Study location
NCT02982993: Completed study of Hepatitis C Infection, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02982993 is a study of Hepatitis C Infection that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 3,906 participants, above the 81-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (4722% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02982993, a study of Hepatitis C Infection, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 3,906 participants
- Enrollment target
- 1
- Study location
Study Summary
This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected. The study will also determine if exposure to human remains, blood and/or bodily fluids during the World Trade Center Health Program activities are associated with Hepatitis C virus infection. These findings would be relevant to the larger United States population, especially to persons born during 1945-1965 who are at high risk of Hepatitis C virus infection.
Primary Outcome
The investigator will measure the prevalence of Hepatitis C virus infection in 3900 World Trade Center Health program members to test the hypothesis that World Trade Center Health program members have an increased risk of Hepatitis C virus infection.
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,906 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-07-12 |
What the finished NCT02982993 record still lists
NCT02982993 is an observational study that tracks outcomes without assigning an intervention. Its 3,906 participants enrollment target places it among the larger protocols in the corpus, above the 81-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (4722% higher).
The record links to 1 condition, with Hepatitis C Infection appearing as the primary indexed condition, and to 0 interventions.
NCT02982993 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02982993 about?
NCT02982993 is a clinical study titled "Hepatitis C Infection in World Trade Center Responders". This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected. The study will also determine if exposure to human remains, blood and/o...
What is the current status of trial NCT02982993?
This trial is currently completed. The enrollment target is 3,906 participants. The study started on 2016-12. Estimated completion is 2018-07-12.
What conditions does trial NCT02982993 study?
This clinical trial studies the following conditions: Hepatitis C Infection.
Who is sponsoring clinical trial NCT02982993?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02982993 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
ACTIVE NOT RECRUITING · Phase 1
-
Study on Immunopathogenesis in HIV and Hepatitis C Coinfection
COMPLETED
-
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia